- Drug Coverage
- Hypertrophic Cardiomyopathy (HCM)
- Vaccines: 2023 Year in Review
- Eyecare
- Urothelial Carcinoma
- Women's Health
- Hemophilia
- Heart Failure
- Vaccines
- Neonatal Care
- NSCLC
- Type II Inflammation
- Substance Use Disorder
- Gene Therapy
- Lung Cancer
- Spinal Muscular Atrophy
- HIV
- Post-Acute Care
- Liver Disease
- Pulmonary Arterial Hypertension
- Safety & Recalls
- Biologics
- Asthma
- Atrial Fibrillation
- Type I Diabetes
- RSV
- COVID-19
- Cardiovascular Diseases
- Breast Cancer
- Prescription Digital Therapeutics
- Reproductive Health
- The Improving Patient Access Podcast
- Blood Cancer
- Ulcerative Colitis
- Respiratory Conditions
- Multiple Sclerosis
- Digital Health
- Population Health
- Sleep Disorders
- Biosimilars
- Plaque Psoriasis
- Leukemia and Lymphoma
- Oncology
- Pediatrics
- Urology
- Obstetrics-Gynecology & Women's Health
- Opioids
- Solid Tumors
- Autoimmune Diseases
- Dermatology
- Diabetes
- Mental Health
Insights on Acne and Rosacea Treatments, Hormonal Therapies, and Depression Screening | AAD 2024
John Barbieri, M.D., MBA, associate professor at Harvard Medical School, discussed various topics based on his presentations at this year’s American Academy of Dermatology meeting about acne and rosacea with Managed Healthcare Executive.
Barbieri shared that in one session, his co-presenters highlighted energy-based therapies, including 1726-nanometer lasers for acne treatment, as well as advancements in acne management for skin of color, focusing on hyperpigmentation and new trials.
Another co-presenter discussed hormonal therapies for acne and rosacea, referencing the recent UK Soccer study on Spironolactone.
Barbieri shared insights on mood changes with Accutane, emphasizing a recent meta-analysis indicating a reduced suicide risk with isotretinoin compared to other acne therapies.
Regarding suicide and depression screening, he suggested using tools like the PHQ-2 or engaging in discussions with patients, stressing the importance of patient-reported outcomes like PHQ-2 and PROMIS measures in clinical practice.
The clinical associate professor at the Rosalind Franklin University Chicago Medical School and founder and director of the Center for Medical Dermatology and Immunology Research in Chicago, spoke in a session over the weekend at the American Academy Dermatology meeting about conditions that may mimic atopic dermatitis.
Read More
